Leaving INTR@PID website

You are leaving INTR@PID Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals who are interested in information on Clinical Research and clinical trials conducted under a partnership between EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, and GSK.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., and have read and understood this disclaimer.

 

Images shown are models for illustrative purposes only

OUR TRIALS

Welcome to INTR@PID Clinical Trials—a program investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF-β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has
not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

Lung cancer icon

LUNG CANCER
 

BILIARY TRACT CANCER icon

BILIARY TRACT CANCER

CERVICAL CANCER icon

CERVICAL CANCER
 

UROTHELIAL CANCER icon

UROTHELIAL CANCER
 

breat cancer icon

BREAST CANCER
 

   

Explore the Knowledge Base